Show simple item record

dc.contributor.authorPinkerton, CRen_US
dc.contributor.authorAblett, Sen_US
dc.contributor.authorBoos, Jen_US
dc.contributor.authorPhilip, Ten_US
dc.date.accessioned2018-09-18T14:45:11Z
dc.date.issued2002-05en_US
dc.identifier8en_US
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, 2002, 38 pp. 1051 - 1058en_US
dc.identifier.issn0959-8049en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2804
dc.identifier.doi10.1016/S0959-8049(02)00021-7en_US
dc.description.abstractPan-European collaboration in studies of novel therapies and treatment strategies in childhood cancer is playing an increasing role in the attempt to improve cure rates. Differences in the systems of various Countries with regard to drug control and ethical issues may lead to problems and delays. This applies in particular to phase I/II studies in children where the ethical considerations may be complex. In this review, the systems in three large countries-UK, France and Germany-are reviewed and current moves within the European Community towards a more standard approach are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.en_US
dc.format.extent1051 - 1058en_US
dc.titleEthical approval for multicentre clinical trials in children: contrasting systems in three European countriesen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0959-8049(02)00021-7en_US
rioxxterms.licenseref.startdate2002-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEUROPEAN JOURNAL OF CANCERen_US
pubs.notesarticle-number: PII S0959-8049(02)00021-7 researcherid-numbers: pinkerton, ross/I-4808-2014 unique-id: ISI:000176637500007en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume38en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorPinkerton, Rossen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record